Ebola hemorrhagic fever (EHF) is a syndrome that can rapidly lead to death within days of symptom onset. The disease directly affects the immune system and vascular bed, with correspondingly high mortality rates [1]. Ebola virus (EBOV) belongs to the family Filoviridae within the order Mononegavirales. The family Filoviridae comprises three genera: Ebolavirus, Marburgvirus, and Cuevavirus. The genus Ebolavirus is further subdivided into five species, each represented by a distinct type virus: Taï Forest ebolavirus (Taï Forest virus, TAFV), Reston ebolavirus (Reston virus, RESTV), Sudan ebolavirus (Sudan virus, SUDV), Bundibugyo ebolavirus (Bundibugyo virus, BDBV), and Zaire ebolavirus (Ebola virus, EBOV). Among these, EBOV is the most prominent member.
EBOV has a ~19 kb negative-sense RNA genome encoding seven genes that produce at least nine proteins: NP, VP35, VP40, GP, sGP, ssGP, VP30, VP24, and L. The GP gene gives rise to three products: full-length GP (cleaved by furin into GP1 and GP2), sGP, and ssGP. The soluble glycoproteins (sGP and ssGP) are nonstructural and secreted. The viral core consists of the RNA genome, NP, VP35, VP30, and L, and is associated with VP24. VP40 is a matrix protein that forms the filamentous particle structure and links the nucleocapsid to the host-derived lipid membrane. GP is a type I transmembrane protein[2-4].
Figure1 Electron micrograph and schematic of the EBOV particle and genome. EBOV particles (blue) on the surface of an infected cell are shown. Abbreviations: EBOV, Ebola virus; GP, glycoprotein; sGP, soluble glycoprotein; ssGP, small soluble glycoprotein; VP, virion protein.
| Protein | Function | Vaccine/Diagnostic Relevance |
| NP | Nucleocapsid formation | PCR/ELISA target |
| VP35 | Interferon (IFN) antagonism | Antiviral drug research |
| VP40 | Viral budding regulation | VLP (virus-like particle) production |
| GP | Viral entry and neutralization | Core vaccine antigen |
| VP30 | Transcription activation | Research applications |
| VP24 | Immune evasion | Antiviral research |
| L | RNA-dependent RNA polymerase | Conserved PCR target |
In May 2026, the World Health Organization (WHO) was alerted of a high-mortality outbreak of illness caused by Bundibugyo virus (BVD, BDBV) in Mongbwalu Health Zone, Ituri Province, Democratic Republic of the Congo (DRC), including deaths among health workers. Bundibugyo virus (BDBV), that forms filamentous virions and is closely related to the Zaire ebolaviruses (EBOV). The virus is one of several that also can cause ebola disease in humans, taking the form of viral hemorrhagic fever. Unlike Ebola virus disease, there is no licensed vaccine or specific therapeutics against Bundibugyo virus, though early supportive care is lifesaving. This outbreak has once again drawn global attention to Ebola disease, underscoring the urgent need for effective detection and prevention products.
Participants in the WHO meeting discussed several vaccines that, in experiments over the past 15 years, have shown varying ability to protect monkeys from BDBV. But the studies had small numbers of animals, and the most promising results came from experimental vaccines not yet approved for human use. All of the vaccines feature the surface protein, spike, of ebolaviruses. One study tested an early version of the Ebola Zaire vaccine, which incorporates the gene for Zaire's spike into harmless vesicular stomatitis virus (VSV). It had limited success, protecting three of four monkeys from death when intentionally infected, or "challenged," with BDBV—but all became ill and had virus in their blood (viremia), meaning they could still transmit the virus [5].
Given the urgent need for better tools to combat BDBV, Creative Diagnostics is closely monitoring the current disease outbreak caused by this virus and has rapidly launched a suite of relevant products to support research into BDBV infection and vaccine development.
References
For research use only, not for use in diagnostic procedures.
| Virus specie | Cat. No | Product Name | Target | Expression System |
| Zaire Ebola virus (EBOV) | DAGA-3013 | Ebola NP antigen [His] | Nucleoprotein (NP) | E. coli |
| DAGZ016 | Ebola-Z glycoprotein (180 aa, mucin like domain) | Glycoprotein (GP) | E. coli | |
| DAGB180 | Ebola virus Glycoprotein (minus the Transmembrane Region) [His] | Glycoprotein (GP) | Insect cells | |
| DAGB181 | Ebola virus Glycoprotein (minus the Transmembrane Region) [HA] | Glycoprotein (GP) | Mammalian cells | |
| DAGB182 | Ebolavirus Soluble Glycoprotein [His] (DAGB182) | Glycoprotein (GP) | Mammalian cells | |
| DAGA-3111 | Recombinant Ebola GP (Zaire) | Glycoprotein (GP) | HEK293 cells | |
| DAGC672 | Recombinant EBOV Nucleoprotein [His] | Nucleoprotein (NP) | HEK293 cells | |
| DAGB179 | Ebola virus-like particles | Glycoprotein (GP), Nucleoprotein (NP), Matrix protein (VP40) | Insect cells | |
| DAGB183 | Ebola virus VP40 matrix protein | Matrix protein (VP40) | E. coli | |
| DAGA-970 | Recombinant ebola zaire nucleoprotein (>95%) [His] | Nucleoprotein (NP) | E. coli | |
| DAG-WT132 | Recombinant Ebola Zaire Nucleoprotein [His] | Nucleoprotein (NP) | HEK293 cells | |
| DAG-WT267 | Recombinant Zaire Ebola Virus glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | HEK293 cells | |
| DAG-WT268 | Biotinylated Zaire Ebola Virus glycoprotein 1,2 (GP1,2) [His,Avi] | Glycoprotein (GP) | HEK293 cells | |
| DAG-WT269 | Recombinant Zaire Ebola Virus glycoprotein 1,2 (GP1,2) [His] | Glycoprotein (GP) | HEK293 cells | |
| DAG-CS144P | Recombinant Ebola Virus VP40 protein [His, GST] | Matrix protein (VP40) | E. coli | |
| Taï Forest virus (TAFV) | DAG-WT7785 | Recombinant Tai Forest ebolavirus (TAFV) Glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | Mammalian cells |
| DAG-WT7786 | Recombinant Tai Forest ebolavirus (TAFV) Glycoprotein 1 (GP1) [Fc] | Glycoprotein (GP) | Mammalian cells | |
| DAG-WT7787 | Recombinant Tai Forest ebolavirus (TAFV) Glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | E. coli | |
| Sudan virus (SUDV) | DAGZ015 | Ebola-S nuclear protein (aa 629-728) | Nucleoprotein (NP) | E. coli |
| DAGA-3107 | Recombinant Ebola GP (Sudan - Nakisamata) | Glycoprotein (GP) | HEK293 cells | |
| DAG-H10347 | SUDV Glycoprotein [His] | Glycoprotein (GP) | Mammalian cells | |
| DAG-H10348 | SUDV Glycoprotein [His] | Glycoprotein (GP) | Insect cells | |
| DAG-WT375 | Recombinant Sudan Virus (SUDV) VLP | Glycoprotein (GP), Nucleoprotein (NP), Matrix protein (VP40) | Insect cells | |
| DAGB188 | Recombinant Sudan virus Glycoprotein (minus the Transmembrane Region) [His] | Glycoprotein (GP) | Insect cells | |
| Reston ebolavirus (REBOV) | DAGB187 | Reston Ebolavirus Glycoprotein (minus the Transmembrane Region) [His] | Glycoprotein (GP), Nucleoprotein (NP), Matrix protein (VP40) | Insect cells |
| DAG-WT7788 | Recombinant Reston ebolavirus (REBOV) Glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | Mammalian cells | |
| DAG-WT7789 | Recombinant Reston ebolavirus (REBOV) Glycoprotein 1 (GP1) [Fc] | Glycoprotein (GP) | Mammalian cells | |
| DAG-WT7790 | Recombinant Reston ebolavirus (REBOV) Glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | E. coli | |
| Bundibugyo virus (BDBV) | DAG-WT1099 | Recombinant Bundibugyo Ebolavirus GP Δmucin | Glycoprotein (GP) | HEK293 cells |
| DAGB178 | Bundibugyo Glycoprotein (minus the Transmembrane Region) [His] | Glycoprotein (GP) | Insect cells | |
| Bombali virus (BOMV) | DAG-WT7791 | Recombinant Bombali virus (BOMV) Glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | Mammalian cells |
| DAG-WT7792 | Recombinant Bombali virus (BOMV) Glycoprotein 1 (GP1) [Fc] | Glycoprotein (GP) | Mammalian cells | |
| DAG-WT7793 | Recombinant Bombali virus (BOMV) Glycoprotein 1 (GP1) [His] | Glycoprotein (GP) | E. coli |
| Cat. No. | Product Name | Test Species |
| PCR-WN-137 | Ebola virus Real Time PCR Kit (50 Reactions, Qualitative) | Zaire ebolavirus, Sudan ebolavirus, Bundibugyo ebolavirus, and Tai Forest ebolavirus |
| PCR-NS2409-1 | Marburg Virus Real Time PCR Kit (50 Reactions, Qualitative) | Marburg Virus |
| PCR-NS2620 | Bundibugyo ebolavirus Real Time PCR Kit (50 Reactions, Qualitative) | Bundibugyo ebolavirus |
| Cat. No. | Product Name | Target Value* |
| NA-GWP-SR-39-L1 | Ebola Virus Zaire Type NP/GP Gene Nucleic Acid Standard Reference (1 mL/vial) | 5000 copies/mL |
| NA-GWP-SR-39-S1 | Ebola Virus Zaire Type NP/GP Gene Nucleic Acid Standard Reference (1 mL/vial) | 2000 copies/mL |
| NA-GWP-SR-39-S2 | Ebola Virus Zaire Type NP/GP Gene Nucleic Acid Standard Reference (1 mL/vial) | 1000 copies/mL |
| NA-GWP-SR-39-S3 | Ebola Virus Zaire Type NP/GP Gene Nucleic Acid Standard Reference (1 mL/vial) | 500 copies/mL |
| NA-GWP-SR-40-L1 | Bundibugyo Virus Type NP Gene Nucleic Acid Standard Reference (1 mL/vial) | 5000 copies/mL |
| NA-GWP-SR-40-S1 | Bundibugyo Virus Type NP Gene Nucleic Acid Standard Reference (1 mL/vial) | 2000 copies/mL |
| NA-GWP-SR-40-S2 | Bundibugyo Virus Type NP Gene Nucleic Acid Standard Reference (1 mL/vial) | 1000 copies/mL |
| NA-GWP-SR-40-S3 | Bundibugyo Virus Type NP Gene Nucleic Acid Standard Reference (1 mL/vial) | 500 copies/mL |
| * After extraction, the copy number is determined by digital PCR; the target value is the expected content. | ||
